Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoidn         arthritis: results of a Phase III randomized study (MIRROR): reply

Tim Shaw

首页> 外文期刊>Rheumatology >Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoidn arthritis: results of a Phase III randomized study (MIRROR): reply

【24h】

Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoidn arthritis: results of a Phase III randomized study (MIRROR): reply

机译：评论：活动性类风湿关节炎患者使用利妥昔单抗的各种重复治疗剂量方案的疗效和安全性：一项III期随机研究（MIRROR）的结果：答复

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Rheumatology》 |2011年第3期|p.632-633|共2页
作者
Tim Shaw;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献

1. Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoidn arthritis: results of a Phase III randomized study (MIRROR) [J] . John J. Carey Rheumatology . 2011,第3期

机译：评论：活动性类风湿关节炎患者使用利妥昔单抗的各种重复治疗剂量方案的疗效和安全性：III期随机研究（MIRROR）的结果
2. Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). [J] . Conway R, Carey JJ Rheumatology . 2011,第3期

机译：评论：活动性类风湿关节炎患者使用利妥昔单抗的各种重复治疗剂量方案的疗效和安全性：一项III期随机研究（MIRROR）的结果。
3. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis:n results of a Phase III randomized study (MIRROR) [J] . Tim M. Shaw Rheumatology . 2010,第9期

机译：活动性类风湿关节炎患者使用利妥昔单抗的各种重复治疗方案的疗效和安全性：III期随机研究（MIRROR）的结果
4. Efficacy Analysis of Preservative-Free Tafluprost and Timolol in Open-Angle Glaucoma and OHT Patients in a Phase-III Study [C] . GrundenJ., Lupinacci R. International Symposium on Ocular Pharmacology and Therapeutics . 2013

机译：在第三阶段研究中，在开放角度荧光眼和OHT患者中无防腐型TaFluprost和蒂莫尔的疗效分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) [O] . Andrea Rubbert-Roth, Paul P. Tak, Cristiano Zerbini, -1

机译：活动性类风湿关节炎患者使用利妥昔单抗重复治疗的各种疗效和安全性：一项III期随机研究（MIRROR）的结果
7. Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR): reply [O] . A. Rubbert-Roth, P. P. Tak, C. Zerbini, 2010

机译：评论：有活性类风湿性关节炎患者中RITUXIMAB各种重复治疗剂量的疗效和安全性：III期随机研究的结果：答复

Comment on: Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoidn arthritis: results of a Phase III randomized study (MIRROR): reply

著录项

相似文献

相关主题

期刊订阅